The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna.
Barbara KiesewetterMarkus RadererGerald W PragerThorsten FuerederChristine MarosiMatthias PreusserMichael KrainerGottfried J LockerThomas BrodowiczChristoph C ZielinskiPublished in: ESMO open (2017)
The ESMO-MCBS scores supported our common treatment strategies and highlight the potential of new immunomodulatory drugs. Our results encourage further development of the ESMO-MCBS.